Rare disease experts
Having previously transformed a startup into a multi-million dollar pharmaceutical company, the Ambrose team is now focussing on sustainable access to life-changing drug treatments for rare disease patients.
Our team
Founder & Chairman
Toby Wilson Waterworth
Toby has led and been part of leadership teams in multiple life science companies that have generated close to $1 billion in shareholder value. His 30 years of experience in North America, Europe, UK and the Middle East includes founding Atlantic Healthcare, which delivered 30x value for early investors, plus senior roles at HD Clinical, Expedeon, Alizyme and Chiroscience. Toby is a Fellow of the Royal Society of Medicine and a Fellow of the Institute of Chartered Accountants in England & Wales.
CFO
Peter McGowan
Peter specializes in strong financial disciplines and establishing new ventures, particularly in life sciences and technology. His 30 years of international experience includes serving as CFO for five different biotechnology companies with a focus on fundraising and closing business development deals. Previously, Peter held senior global finance positions at Mundipharma and PPD. He is a Fellow of the Association of Chartered Certified Accountants.
Corporate Communicatons
Juliet Burns
Juliet is a multi-lingual communications professional focused on helping growing rare diseases companies communicate effectively. With more than 15 years experience across Europe and the USA working on clinicial trial recruitment and disease awareness campaigns, academic symposia, corporate communications, and product development for patient platforms, she has extensive experience across all ends of healthcare. She has delivered projects for big pharma, but as an all-rounder she’s most passionate about supporting entrepreneurial teams and new businesses.
Clinical Development and Regulatory Strategy
Dr Nick Meyers
Nick is an experienced Program Director with 30 years’ experience in the industry (in Pharma, biotech and CROs), advising clients on R&D strategy, as well as planning and overseeing out-sourced, early- and late-stage development projects globally, covering all key aspects of development (CMC, nonclinical, clinical, and regulatory), including directly overseeing 14 clinical studies (Phases 1-3). Nick has developed helped to develop products spanning different treatment modalities and therapeutic areas, including small molecules for IBS, Parkinson’s disease, ALS, and chronic pain, biologics for acromegaly and haemodialysis access, and gene therapies for non-muscle invasive bladder cancer, and has managed 3 BLA, NDA & MAA submissions. Importantly, from 2001-2008 whilst at Alizyme Therapeutics plc, Nick managed the development of renzapride for the treatment of IBS-C and IBS-A. Nick has a PhD in molecular bacteriology and from Cranfield University and prior to joining the industry, worked as a research fellow in virology at the AFRC IAH and at the University of Cambridge.
Manufacturing
Mike Webb
Mike specializes in chemistry, manufacturing and controls (CMC) in drug development, from late discovery to launch and beyond. He has been involved in eight worldwide marketing submissions and led departments of up to 150 scientists in a 30-year career at GSK. Mike has a PhD in analytical chemistry from Imperial College London.
Our medical advisory board
Canada
Professor Brian Feagan
Professor of Medicine at the Schulich School of Medicine & Dentistry, Ontario Dr Brian Feagan, a Gastroenterologist and Professor of Medicine, has dedicated his research to developing outcome measures for novel therapeutics and conducting large-scale multi-center clinical trials. With over 30 years of experience, he has authored over 550 articles, served as a Principal Investigator on more than 140 clinical trials and been named one of the top five experts globally for Crohn’s disease.
UK
Dr Shabbir Moochhala
Consultant Nephrologist and Physician, Royal Free Hospital Dr Shabbir Moochhala is an experienced consultant nephrologist at the Royal Free Hospital in London. He has specialist expertise in rare diseases and is a principal investigator for several international medical trials. He lectures internationally and leads in rare kidney disease at national level, including as chair of an NHS Rare Disease Collaborative Network in rare kidney stone disease.
UK
Dr Jamie Duckers
National Clinical Lead for Rare Disease, NHS Wales Dr Jamie Duckers, a Respiratory Physician, has made significant contributions to healthcare and research in Wales. He serves as the National Clinical Lead for Rare Disease, Wales, and research lead for the  All-Wales Adult Cystic Fibrosis Service, and is actively involved in various advisory groups related to cystic fibrosis and respiratory health. His experience also encompasses exploring early stakeholder engagement to ensure rare diseases patient priorities are being met early in the development of new drugs.
UK
Professor Kevin Mills
Head of the Translational and Clinical Omics Group at University College London based at the Great Ormond Street Institute of Child Health Professor Mills’ research aims to combine state-of-the-art technology with AI/Machine Learning to find new drug targets, identify new biomarkers and develop new and more precise tests. His research group is unique in that they can use their omic capability to help understand disease mechanisms and identify drug targets but can also translate any biomarker into a test to NHS or Industry accredited standards.